Measuring Spending Levels - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Measuring Spending Levels
Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and type of spending made in 2010 and planned for 2011.

Pharmaceutical Technology
Volume 35, Issue 3, pp. 50-62

Figure 6: Level of industry innovation in select manufacturing areas during the past two years (2009 and 2010). API is active pharmaceutical ingredient.
Also, fewer companies will buy equipment and machinery for expanding facilities or other upgrades in 2011. More than one-half (57.7%) of respondents said expanding manufacturing facilities had "high" or "medium" impact or on their planned expenditures in 2011 compared with their spending in 2010, when almost two-thirds regarded these factors as important. Almost 60% (59.7%) said adding enhancements, upgrades, and/or innovative technology was either of "high" or "medium" impact for planned purchases in 2011, down slightly from the 63.9% that said so in 2010. Slightly more respondents in 2011 (68.9%) than in 2010 (64.4%) regard replacing existing equipment as a "high" or "medium" impact factor in purchasing (see Figures 4 and 5).

Figure 7: Level of industry innovation for select equipment and machinery types during the past two years (2009 and 2010).
Outsourcing will be less influential in purchasing decisions in 2011. For 2011, 38.7% of respondents said that outsourcing to decrease capital expenditures was a high- or medium- impact factor as compared with 43.3% who said so in 2010 (see Figures 4 and 5). For 2011, 16.0% said outsourcing to reduce capital spending had "high" impact, and 22.7% said it had "medium" impact (see Figure 5).

Respondents' profiles
Some newer technologies will have more import in purchasing. The survey showed that 42.8% of respondents regard improving security and anticounterfeiting capabilities as a high- or medium-impact factor for their planned purchases in 2011 compared with 45% who did for actual purchases made in 2010. More companies will spend to apply QbD in 2011 and a similar number of respondents cite PAT as an influential. (see Figures 4 and 5). More than half of respondents (52.2%) said that applying QbD is a high- or medium- impact factor for planned purchases in 2011, slightly more than the 50/% who did for actual spending in 2010 (see Figures 4 and 5). For 2011, 44.4% of respondents said PAT will have either "high" or "medium" impact for planned purchases, compared with 47.0%, who said it had that importance in 2010.


About two-third (65.2%) of respondents said that innovation is "extremely" or "very" important in their purchasing decisions for equipment and machinery. In evaluating innovation, respondents thought the level of innovation was highest during the last two years in biologic API manufacturing (33.9% said so) and equipment for quality assurance/quality control (26.7% said so) (see Figure 6). Innovation was considered the lowest for high-potency/high-containment manufacturing for APIs and finished products, both for which 22.1% of respondents said there has been no innovation during the past two years (see Figure 6). In terms of specific equipment types, the highest-ranked area was for innovation in process control and automation, followed by disposables for biopharmaceutical manufacturing, laboratory equipment, and analytical instrumentation. Innovation in tablet presses, capsule-filling machines and equipment for vial- or syringe-filling ranked the lowest (see Figure 7). Roughly two-thirds of respondents do not use continuous processing for finished products (66.9%) or APIs (69.4%). For disposables or single-use components, 63.9% use them in biopharmaceutical manufacturing, and 36.1% do not. For future purchases, respondents show a slight preference for a mix of stainless-steel equipment and disposables (35.7%), 34.3% will purchase stainless-steel equipment only, and 27.1% will only buy disposables.


1. P. Van Arnum, Pharm. Technol. 34 (4), 48–56 (2010).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here